Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging | MicrobiomeTrials← Back to trialsNCT07613099
Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2026-06-23Est. Completion: 2031-05-26
Enrollment target: 210 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
Partial Thickness Rotator Cuff Tears
The goal of this study is to evaluate the efficacy and safety of allogeneic dermal fibroblasts (TPX-115) compared to pla…
La Mesa, United StatesEst. completion May 2027
Systemic Lupus Erythematosus (With and Without Nephritis)Idiopathic Inflammatory MyopathySystemic Sclerosis
This is a first-in-human, single-arm, open-label study evaluating the safety, tolerability, and preliminary efficacy of …
Phoenix, United StatesEst. completion Feb 2028